key: cord-0743112-121tmyah
authors: Cohen, Jordana B; South, Andrew M; Shaltout, Hossam A; Sinclair, Matthew R; Sparks, Matthew A
title: Renin-Angiotensin System Blockade In The Coronavirus Disease 2019 Pandemic
date: 2021-02-02
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab026
sha: 18763a09e1a6b81f0de82aa43de1b71e893322d2
doc_id: 743112
cord_uid: 121tmyah

In the early months of the coronavirus disease 2019 (COVID-19) pandemic, a hypothesis emerged suggesting that pharmacologic inhibitors of the renin-angiotensin system (RAS) may increase COVID-19 severity. This hypothesis was based on the role of angiotensin-converting enzyme 2 (ACE2), a counter-regulatory component of the RAS, as the binding site for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), allowing viral entry into host cells. Extrapolations from prior evidence led to speculation that upregulation of ACE2 by RAS blockade may increase the risk of adverse outcomes from COVID-19. However, counterarguments pointed to evidence of potential protective effects of ACE2 and RAS blockade with regard to acute lung injury, as well as substantial risks from discontinuing these commonly used and important medications. Here we provide an overview of classic RAS physiology and the crucial role of ACE2 in systemic pathways affected by COVID-19. Additionally, we critically review the physiologic and epidemiologic evidence surrounding the interactions between RAS blockade and COVID-19. We review recently published trial evidence and propose important future directions to improve upon our understanding of these relationships.

Early in the coronavirus disease 2019 (COVID- 19) pandemic, a hypothesis emerged proposing that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), inhibitors of the renin-angiotensin system (RAS), may increase the risk of development and severity of COVID-19. 1 This hypothesis was based on limited physiologic evidence coupled with initial clinical descriptions of individuals hospitalized with COVID-19. Considering that ACEIs/ARBs are among the most prescribed medications globally, 2, 3 the hypothesis of a potential interaction between RAS blockade and COVID-19 quickly garnered momentum in the lay press and medical community. Several medical societies quickly reacted, unanimously recommending that patients continue to take these medications until more information is available. 4, 5 The physiologic evidence for the hypothesis was based in the role of angiotensin-converting enzyme 2 (ACE2), a counter-regulatory component of the RAS, as the primary binding site for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), facilitating SARS-CoV-2 entry into host cells. 6, 7 8 Prior evidence suggested that ACEIs/ARBs upregulate ACE2, 9, 10 and individuals hypothesized that increased ACE2 expression may increase susceptibility to SARS-CoV-2 infection, increasing the risk of development and severity of COVID-19 ( Figure) . 1 However, counterevidence supported a protective role of ACE2 as well as possible differential effects between ACEIs and ARBs on the risk of acute lung injury. 11, 12 Epidemiologically, the hypothesis was based on findings from initial case series, which showed that a high proportion of individuals hospitalized with COVID-19 had conditions commonly treated with RAS blockade, including hypertension, diabetes, and heart disease. [13] [14] [15] These initial case series did not provide information on the frequency of ACEI/ARB use nor could they be used to draw conclusions about the relationships between these risk factors with adverse outcomes. 16 The current review aims to provide an overview of classic RAS physiology and its interaction with SARS-CoV-2. We examine the role of ACE2 in hypertension; target organ effects in the heart, kidneys, and brain; the lungs; and thromboembolic pathways; and how ACE2 may impact host responses to SARS-CoV-2 infection. We also evaluate the strengths and limitations of the current physiologic and epidemiologic evidence of the relationships between RAS blockade and COVID-19 and propose approaches to improve our understanding of these relationships in future studies.

The RAS plays crucial roles in regulating blood pressure (BP), including fluid and electrolyte balance and vascular tone. Targeting the RAS with ACEIs/ARBs constitutes a very effective strategy to treat hypertension. Since the discovery of angiotensin-converting enzyme (ACE) in 1956, 17 our understanding of the RAS as an endocrine system had been focused primarily on studying the interaction of angiotensin II (Ang II) with the Ang II type 1 (AT 1 ) receptor to raise BP. However, our understanding of the RAS shifted dramatically with the identification of angiotensin-(1-7) (Ang- [1] [2] [3] [4] [5] [6] [7] ) in the late 1980s as the first amino-terminal angiotensin peptide possessing biological actions that oppose those of Ang II. [18] [19] [20] [21] [22] ACE2 catalyzes the formation of Ang-(1-7) from Ang II 23, 24 and thus plays a critical role in RAS counter-regulation by decreasing Ang II content and increasing Ang-(1-7) content, among other roles. 25 Mice lacking the ACE2 gene had an enhanced Ang II pressor response. 26 ACE2-deficient mice on the C57BL/6 background had modestly increased BP compared to controls at baseline but acute Ang II infusion increased plasma Ang II concentrations and BP to a greater extent in the ACE2-deficient mice compared to controls. 27 In rat models of hypertension, the renal ACE2 messenger ribonucleic acid (mRNA) and protein levels and expression are markedly lower than that observed in normotensive controls. 28 ACE2 enzymatic activity is not limited to the RAS; ACE2 can metabolize and inactivate other peptides such as pyr-apelin 13 and apelin 17, the dominant apelin peptides, 29 which have hypotensive 6 effects. 30 Indeed, ACE2 knockout mice had potentiated hypotensive responses from pyr-apelin 13 that corresponded to greater plasma apelin levels and that the selective ACE2 inhibitor MLN-4760 blocked. 31 On the other hand, in select models, lisinopril may increase cardiac ACE2 mRNA expression but not activity, while losartan may increase both cardiac ACE2 mRNA expression and activity, in addition to their BP-lowering effects in Lewis rats. 9

Heart ACE2 plays a critical role in cardiovascular pathology development, especially heart failure. ACE2 is present in the membrane of most epithelial cells, cardiac myocytes, vascular smooth muscle and endothelial cells, the adventitia of large blood vessels, and neural tissues. 32 ACE2-deficient mice exhibit severely reduced cardiac contractility. 28 Chronic ACE2 inhibition with MLN-4760 in transgenic rats increased cardiac Ang II content and significantly increased left ventricular anterior, posterior, and relative wall thicknesses, as well as increased interstitial collagen fraction area and cardiomyocyte hypertrophy. 33 Furthermore, increasing Ang-(1-7) content improves heart function, reverses cardiac remodeling, and restores vascular responsiveness after myocardial infarction, 34, 35 while recombinant human ACE2 successfully reduced cardiac hypertrophy and dysfunction in preclinical models of heart failure. 36 On the other hand, transgenic mice with increased cardiac ACE2 expression had a high incidence of sudden death due to progressive conduction and rhythm disturbances with sustained ventricular tachycardia and terminal ventricular fibrillation. 37 Thus, the exact role of ACE2 in cardiovascular disease, and in particular heart disease, remains incompletely understood.

The ACE/Ang II and ACE2/Ang-(1-7) pathways are co-expressed throughout the kidney, including in the arterioles, the epithelium, endothelium, and podocytes of the glomerulus, and throughout the tubular epithelium but in particular, the proximal tubular brush border. 10, 38, 39 The ACE2/Ang-(1-7) pathway generally opposes Ang II's actions to promote renal vasodilation, sodium and water excretion, and to prevent or attenuate inflammation and fibrosis. 40 In rats, ischemia-reperfusion decreased renal ACE2 mRNA and protein expression, and enzymatic activity, altered renal Ang-(1-7) content, and increased renal Mas receptor mRNA expression. 42, 44 These effects were magnified in ACE2 knockout mice and mitigated in ACE2 transgenic mice. 44 Diabetes reduced renal ACE2 mRNA and protein expression and renal Ang-(1-7) concentration despite increased renal and plasma ACE2 activity, effects that MLN-4760 enhanced. 46 Loss of ACE2 and the Mas receptor lead to Ang II-dependent glomerular injury and kidney dysfunction. 47, 48 Recombinant human ACE2 increased plasma ACE2 activity, increased Ang-(1-7) and decreased Ang II renal and plasma concentrations, and improved kidney function and BP in diabetic mice. 46 Further, conditions of endogenous RAS activation likely enhance, or are required for, Ang-(1-7)'s counter-regulatory actions. 49

The role of the brain RAS in the central regulation of cardiovascular physiology and the autonomic nervous system is clear from studies of wild-type and transgenic animals. As in other tissues, the balance between the ACE/Ang II and ACE2/Ang-(1-7) pathways in the brain is crucial for 8 cardiovascular health. 50 Ang II AT 1 receptor signaling in the brain increases BP via enhanced sympathetic outflow, 51, 52 vasopressin release, 53 and cardiac baroreflex resetting. 50, 54, 55 In the spontaneously hypertensive rat, upregulation of brain RAS components (i.e., angiotensinogen, ACE, Ang II, and AT 1 receptor) preceded and sustained hypertension development, which intracerebroventricular captopril injection reversed. 56 Meanwhile, the brain ACE2/Ang-(1-7) pathway counter-regulates Ang II's effects on cardiovascular function, autonomic function, and cognition. ACE2 is expressed throughout the brain, including in nuclei involved in central regulation of cardiovascular function in the brainstem and non-cardiovascular areas such as the motor cortex and raphe. 57 In humans, ACE2 mRNA expression in the brain was at least 10-fold lower than ACE. 58 Ang-(1-7) reduced BP and improved baroreflex function in animal models of hypertension. 54, 59-61 ACE2-knockout mice exhibited reduced cardiac baroreflex function compared to wild type, which intracerebroventricular losartan injection restored. 62 ACE2 over-expression in the rostral ventrolateral medulla reduced BP in spontaneously hypertensive rats, 63 which could be due to ACE2induced Ang II degradation as well as AT 1 receptor down-regulation in this region. In addition, ACE2 overexpression in the subfornical organ prevented Ang II-mediated pressor and thirst responses. 64 ACE2 overexpression in select areas of the brain in transgenic mice reduced sympathetic outflow and improved autonomic function. 65 Frontal cortex ACE2 activity was reduced in an Alzheimer disease mouse model. 66 Intraperitoneal diminazene aceturate administration, an established ACE2 activator, lowered hippocampal Aβ and restored cognition in mid-aged symptomatic mice via increased ACE2 activity, restored Mas receptor levels, and decreased extracellular regulated kinase 1/2 signaling. 67

The RAS regulates pulmonary vascular tone, integrity of the alveolar capillaries, and the immune system response to lung injury, among other functions. While several pulmonary cell types express the RAS, including alveolar epithelial cells, resident immune cells, and pulmonary vascular endothelial and smooth muscle cells, ACE/Ang II pathway expression is typically much stronger than ACE2/Ang-(1-7), which is predominantly limited to type II alveolar epithelial cells. 32, 68 Notably, lung injury increases ACE/Ang II but downregulates ACE2/Ang-(1-7), further driving inflammation and fibrosis. 69, 70 Ang II-AT 1 receptor signaling increases pulmonary vasculature permeability, promotes immune system cell migration, activation, and differentiation, and induces alveolar epithelial cell apoptosis and fibroblast differentiation. [71] [72] [73] [74] Ang-(1-7) acts in part through the Mas receptor to block these Ang II-mediated effects. 75 In various models of acute lung injury (acid, sepsis, endotoxin, influenza), ACE2-knockout mice had greater increases in inflammatory cell infiltration and lung edema that were associated with increased pulmonary vascular permeability, hyaline membrane formation, and elastance, and greater decreases in oxygenation compared to wild-type mice. 76, 77 Intraperitoneal recombinant human ACE2 administration improved elastance and edema and decreased Ang II content in acid-treated ACE2knockout and wild-type mice. 76 Similarly, acid exposure decreased ACE2 protein expression in wild-type mice and increased lung Ang II concentrations to a greater extent in ACE2-knockout mice compared to wild-type mice. 76 SARS-CoV Spike protein binds to ACE2 on type II alveolar epithelial cells and subsequently downregulates ACE2 expression, increases lung Ang II concentration, and enhances AT 1 receptor-mediated injury. 6 While this has been postulated to occur in SARS-CoV-2 as a mediating factor in COVID-19, to date there have been no studies to confirm this pathophysiologic process. 7 Mast cells recruited to areas of lung injury can release chymase, which could lead to further increases in Ang II. 78, 79 Loss of pulmonary ACE2 activity can also drive lung inflammation via increased [des-Arg 9 ]-bradykinin (DABK)/bradykinin receptor B1 activation and possibly via alterations to the apelin pathway. 80, 81 In rats exposed to lipopolysaccharide plus mechanical ventilation, treatment with losartan or cyclic Ang-(1-7) increased ACE2 activity and Ang-(1-7) concentration in bronchoalveolar lavage fluid, improved oxygenation, and reduced lung injury compared to placebo. 69 Pretreatment or treatment with losartan or Ang-(1-7) reduced acute lung injury and fibrosis, while pretreatment or treatment with the Mas receptor antagonist A-779 not only reversed this protective effect but enhanced progression to fibrosis. 82, 83 In humans, limited clinical evidence supports the experimental evidence. ACE and ACE2 activity in bronchoalveolar lavage fluid correlated weakly with inflammatory markers in patients with acute respiratory distress syndrome. 84 In a pilot study in patients with acute respiratory distress syndrome, intravenous recombinant human ACE2 decreased Ang II levels and increased Ang-(1-7) levels in plasma but did not affect lung physiology or outcomes. 85

The ACE2/Ang-(1-7) pathway is crucial to maintaining vascular endothelial integrity, in part via nitric oxide release, and is expressed by platelets and thus mediates vascular inflammation and the clotting cascade. 32, 86-88 Ang II-AT 1 receptor binding stimulates inflammatory cell recruitment and cytokine release to promote thrombosis, which ACE2/Ang-(1-7) can mitigate in part via negatively modulating plasminogen activator inhibitor-1, extracellular signal regulated kinase 1/2, and nicotinamide adenine dinucleotide phosphate oxidase and decreasing oxidative stress. [89] [90] [91] [92] [93] ACE2 knockout mice demonstrate increased expression of interleukin-6, monocyte chemoattractant protein-1, and vascular cell adhesion molecule-1, increased macrophage response to Ang II, and increased endothelial cell activation and responsiveness to tumor necrosis factor-α. 94 In a hypertension rat model, greater thrombus formation was associated with decreased ACE2 activity, and 11 ACE2 inhibition increased thrombus weight while ACE2 activation attenuated thrombus formation and reduced platelet attachment. 95 Decreased ACE2 could also promote thrombosis via modulation of bradykinin/kallikrein. 96 SARS-CoV-2 decreased platelet ACE2 levels in vitro, and patients with COVID-19 had lower platelet ACE2 levels compared to healthy controls. 87 Platelets express transmembrane protease serine 2, and SARS-CoV-2, via the Spike protein, was shown to bind directly to platelets, potentiate platelet activation, enhance platelet spread, and stimulate coagulation factor and inflammatory cytokine release from platelets via mitogen-activated protein kinase pathways in vitro and in vivo, while recombinant human ACE2 suppressed these effects. 87

Despite the critical roles that ACEIs/ARBs have in diminishing adverse cardiovascular and kidney outcomes, concern emerged early in the pandemic that these drugs may be leading to adverse outcomes in patients with COVID-19. These concerns stemmed from the theory that ACEIs/ARBs may promote SARS-CoV-2 viral entry into cells by increasing ACE2 expression in respiratory epithelial cells ( Figure) . 8 Some animal model studies have shown that ACEIs/ARBs can upregulate ACE2 expression and activity in heart and kidney tissue. 9, 10 Furthermore, a 2015 study in humans found that participants taking the ARB olmesartan had higher urinary ACE2 levels compared with control participants, 97 while a recent study looking at ACEI/ARB use in patients with and without COVID-19 found that plasma ACE2 activity was higher in patients with COVID-19 who were taking ACEIs compared with those with COVID-19 who were not taking ACEIs/ARBs. 98 It was thus postulated that ACEIs/ARBs may upregulate ACE2 in the lungs.

While higher ACE2 mRNA expression in the lungs has been noted in patients who have comorbidities that are frequently found in patients with severe COVID-19, 99 such as diabetes mellitus, hypertension, and chronic obstructive lung disease, there have yet to be any animal or human studies to definitively demonstrate that ACEIs/ARBs upregulate ACE2 in the lungs. In fact, Wysocki et al. demonstrated in a mouse model that ACEI/ARB administration had no detectable effect on ACE2 levels or activity in the lungs. 100 Additionally, conflicting evidence exists in human studies in that there is no consistent association between ACEIs/ARBs and circulating ACE2 concentration or activity. [101] [102] [103] Furthermore, it is unclear if the overexpression of ACE2 and its theoretical effect of SARS-CoV-2 viral entry in the lungs of patients with chronic illnesses is the cause of worse outcomes in COVID-19, or if patients with these comorbidities are simply more prone to adverse outcomes because of their underlying illnesses.

Further complicating the issue is the fact that there exists limited evidence (in both animal model and human studies) that ACEIs/ARBs may actually be beneficial in patients with various viral pneumonias. Henry et al. described a cohort of >500 patients with viral pneumonia in Texas from 2011 to 2014 in which patients who continued their ACEI during hospitalization had a 75% lower odds of intubation and mortality. 104 However, patients who were taking ACEIs prior to admission had 3-fold higher odds of death compared with those not taking ACEIs, raising the question of whether ACEIs may have been preferentially continued in healthier patients (i.e. implying several sources of bias including collider and selection bias 105 ). A 2005 study using a mouse model examined the original SARS-CoV, which was responsible for the SARS epidemic in 2002. 6 The authors found that in a mouse model of acid aspiration-induced acute lung injury who were treated in vivo with the SARS-CoV Spike protein, losartan attenuated pulmonary edema and lung injury severity. This was thought to be due to losartan's effect of blocking the AT 1 receptor and hence attenuating the effect of the excess Ang II generation and subsequent AT 1 receptor signaling from Spike protein-induced ACE2 downregulation (Figure) . 6

Given their differential effects on the RAS, it is possible that ACEIs may be detrimental in patients with COVID-19 while ARBs may be neutral or beneficial. ACE, in addition to converting Ang I to Ang II, breaks down bradykinin. Bradykinin is a vasoactive peptide that contributes to BP regulation and inflammation via its ability to increase vascular permeability and cause vasodilatation of blood vessels throughout the body. Bradykinin and its active metabolite, DABK, act on two G-protein-coupled receptors, B 1 and B 2 ; DABK binds mainly to B 1 while bradykinin binds mainly to B 2 . 80, 106, 107 The B 2 receptor is constitutively expressed in many cell lineages and responsible for a number of bradykininmediated effects such as vasodilation, hypotension, and increased vascular permeability. The B 1 receptor, however, is often absent in normal tissues and is instead expressed during inflammatory states such as septic shock and lung inflammation. 108 Furthermore, B 1 receptor activation can occur concomitantly with the pro-inflammatory chemokine C-X-C motif chemokine 5 (CXCL5) release and neutrophil recruitment to the lung. 80 Since ACEIs act by competitively inhibiting ACE, the addition of ACEIs can result in decreased bradykinin breakdown and elevated bradykinin levels, causing the cough and occasionally angioedema that can occur in patients taking ACEIs, along with possible lung injury. 12,

Roche et al. discuss a separate bradykinin hypothesis that suggests that SARS-CoV-2-mediated ACE2 depletion may lead to bradykinin dysregulation, including increased bradykinin and DABK, leading to worsened acute lung injury and respiratory distress. 113 Since ARBs do not competitively inhibit ACE, they have no known role in contributing to elevated bradykinin levels and thus should not precipitate further bradykinin-mediated lung injury. If dysregulated bradykinin signaling turns out to be a major mechanism by which patients with COVID-19 experience lung injury, it is plausible that concomitant ACEI use could be detrimental whereas ARB use would not (Figure) .

The conflicting evidence and hypotheses regarding the relationship of RAS blockade with ACE2 expression and COVID-19-related outcomes resulted in a surge of studies aiming to assess 1) the safety of continuing and 2) the effectiveness of initiating ACEIs/ARBs in the management of COVID-19. 115 To date, the authors have repeatedly concluded that ACEIs/ARBs do not seem to be associated with testing positive for SARS-CoV-2 among symptomatic patients nor with more severe COVID-19. They have also concluded that evidence remains lacking on the effect of ACEIs/ARBs on the risk for mild or asymptomatic disease or for the treatment of COVID-19. Thus, most observational studies support physiologic evidence suggesting that ACEIs/ARBs do not affect ACE2 expression, concentration, or activity. [100] [101] [102] [103] 

Given the enormous potential public health impact, the urgency of the study question yielded a paradigm for the utility of real-world evidence in identifying safety and effectiveness of pharmacologic therapies. 116 Observational evidence can be particularly helpful for answering study questions where randomized trials are infeasible, impractical, or unethical, for example due to the need for large sample sizes, long duration of follow-up, or evaluation of the natural history of a disease process. 117 Observational study designs were best suited to evaluate the safety of prior ACEI/ARB use compared with other antihypertensive therapies with regard to risk of developing symptomatic COVID-19; this question necessitated urgent answers to guide the ongoing care of patients during the pandemic and could not be readily or quickly answered with randomized controlled trials. Accordingly, observational studies provided rapid, crucial evidence to support the safety of continuing ACEIs/ARBs during the COVID-19 pandemic among outpatients who were already prescribed these medications. 115, 118, 119 However, understanding the rapid pace of implementation, many of the observational studies published early in the pandemic had important limitations. 105 Table 1 defines and describes common limitations of these studies that are essential to consider when interpreting the findings. For example, many studies did not address potential major confounders, 117 such as confounding by indication for use of ACEIs/ARBs as opposed to other antihypertensive agents (e.g., due to proteinuric chronic kidney disease or heart failure with reduced ejection fraction) and unmeasured confounding due to inadequate access to healthcare or SARS-CoV-2 testing. Several studies may have introduced collider bias by restricting the study samples to individuals who were hospitalized or had symptomatic COVID-19, which can result in spurious associations between ACEIs/ARBs and COVID-19. 120, 121 Additionally, several studies reported a lower risk of COVID-19 severity among hospitalized patients on ACEIs/ARBs compared with those not on these agents; however, a number of these studies introduced time-dependent bias, or failing to adequately account for the timing and duration of ACEIs/ARBs while hospitalized. [122] [123] [124] [125] 

Several of the limitations of existing observational evidence can be addressed with careful considerations about study design and use of analytic methods that facilitate causal inference. 105 For example, directed acyclic graphs are causal diagrams that demonstrate the causal relationships between exposures and outcomes, as well as antecedents (causes) and descendants (effects) of these factors that can be sources of several types of bias. 126 Thus, directed acyclic graphs are helpful tools in visualizing and identifying potential sources of bias, such as confounding, selection bias, and collider bias, which can then guide the identification of an optimal data source, study sample, study design, and analytic method to appropriately address these potential sources of bias. For example, in studies of hospitalized patients, use of methods that address ACEI/ARB use as a time-varying exposure can mitigate timedependent bias. Sensitivity analyses, such as evaluation of carefully selected negative controls, can also provide important insights into the potential effects of biases on the primary findings. 127 Ultimately, randomized controlled trial evidence provides the highest quality evidence to identify the safety of continuing RAS blockade and the potential efficacy of treatment with RAS blockade in COVID-19 ( Table 2) . Similar to observational evidence, early reports from trials demonstrate no elevated risk of COVID-19 incidence or severity in interim analyses of high-risk participants randomized to ACEI versus placebo 128 or from continuation versus withdrawal of ACEIs/ARBs in patients hospitalized with COVID-19. 129, 130 The first peer reviewed randomized controlled trial results were published from the Randomized Elimination or ProLongation of ACEI/ARBs in COVID-19 (REPLACE COVID) trial in January 2021, corroborating early reports from other trials presented at scientific meetings or via preprint. 131 In this multicenter, international study, 152 patients hospitalized with COVID-19 were randomized to continue versus discontinue their ACEI/ARB upon admission. Patients were excluded with contraindications to continuing or discontinuing ACEI/ARB therapy, such as hyperkalemia or heart failure with reduced ejection fraction, respectively. The authors observed no difference between randomization arms with regard to the primary endpoint (a hierarchical global rank score in which patients were ranked by time to death and severity of illness), death, mechanical ventilation or intensive care unit admission, length of hospitalization, length of intensive care unit admission, or multiorgan dysfunction measured by the area under the curve of a modified sequential organ failure assessment score. 131 Additionally, there were no differences in blood pressure, serum potassium, and serum creatinine during hospitalization across the two randomization groups. 131 Strengths of the trial include its pragmatic approach and wide scope of participants enrolled from seven countries across three continents, making the findings generalizable to a broad range of hospitalized patients with COVID-19.

The main limitation is the small sample size; 132 the authors noted that the small sample size was supported by the use of the global rank score as the primary endpoint, which allows for smaller sample sizes than other commonly used endpoints. 131, 133 While randomized controlled trials provide the highest quality evidence, they have important limitations to consider, some of which are amplified during a pandemic. Randomized controlled trials are often not practical or feasible to answer important study questions due issues of cost, ethical concerns, and/or rapid pace of recruitment necessary to provide answers early in the course of a pandemic. For example, while a randomized trial was initiated to evaluate the risk of continuing versus discontinuing ACEI/ARB use and testing positive for SARS-CoV-2 among outpatients (NCT04330300), the study required a very large sample size (>2400 participants) and was suspended, in part due to challenges with efficient enrollment. Additionally, randomized trials are unlikely to have adequate statistical power to be able to evaluate potentially high-risk subgroups and important effect modifiers.

For example, the REPLACE COVID trial could not assess whether ACEIs have differential effects than ARBs with regard to COVID-19-related outcomes. High quality observational studies that appropriately apply methods to facilitate causal inference have the potential to provide critical insights into these relationships.

In conclusion, the RAS plays a major role in mediating many physiological and inflammatory responses in a variety of important cardiovascular tissues. RAS blockade has an important role in treating hypertension, cardiovascular disease, and kidney disease. However, mixed physiologic evidence exists regarding the role of ACEIs/ARBs in COVID-19. Observational evidence thus far has important limitations but suggests no elevated risk from continuing ACEIs/ARBs in patients already prescribed these medications. Randomized trials will provide important information on the safety and effectiveness of continuing and introducing RAS blockade in the treatment of COVID-19. Future observational studies, when carefully designed to appropriately address important sources of bias, can provide crucial information on potential differential effects of ACEIs and ARBs in acute lung injury and other adverse outcomes in COVID-19.

The authors deny any disclosures related to this review. The results presented in this paper have not been published previously in whole or part, except in abstract format FUNDING JBC is supported by K23-HL133843 and R01-HL153646 from the National Heart, Lung, and Blood Institute; AMS is supported by K23-HL148394, R01-HL146818 and L40-HL148910 from the National Heart, Lung, and Blood Institute; HAS is supported by SDG-27370015 from the American Heart Association, R01-AG066910 from the National Institute on Aging, R01-DK124639 and U01-DK073974 from the National Institute of Diabetes, and Digestive, and Kidney, and R01-HL146816 from the National Heart, Lung, and Blood Institute. The funding sources had no involvement in the preparation of this article.

Nakamoto H, Ferrario infusion improves blood pressure regulation in antenatal betamethasone-exposed sheep and reveals 

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey

ClinCalc DrugStats Database, Version 21.0. ClinCalc

The Coronavirus Conundrum: ACE2 and Hypertension Edition

Coronavirus disease 2019 and hypertension: the role of angiotensin-converting enzyme 2 and the renin-angiotensin system

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

COVID-19, ACE2, and the cardiovascular consequences

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan

Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19

A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations

The preparation and function of the hypertensinconverting enzyme

Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats

Identification of angiotensin-(1-7) in rat brain. Evidence for differential processing of angiotensin peptides

Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide

Angiotensin-(1-7): a new hormone of the angiotensin system

Pathways of angiotensin formation and function in the brain

Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II

Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure

Angiotension-(1-7) and antihypertensive mechanisms

Regulation of blood pressure by the angiotensin-converting enzyme homologue ACE2 (abstract)

Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Hydrolysis of biological peptides by human angiotensinconverting enzyme-related carboxypeptidase

Apelin-13 in blood pressure regulation and cardiovascular disease

Angiotensin-Converting Enzyme 2 Metabolizes and

Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System

the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats

Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation

Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats

Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure

Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins

Renal ACE2 expression in human kidney disease

Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes

activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease

Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway

Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II

AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes

Differential regulation of cytokine release and leukocyte migration by lipopolysaccharide-stimulated primary human lung alveolar type II epithelial cells and macrophages

Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages

Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections

Role of chymasedependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats

Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene

Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration

Apelin-13 Administration Protects Against LPS-Induced Acute

Lung Injury by Inhibiting NF-kappaB Pathway and NLRP3 Inflammasome Activation

Angiotensin-(1-7) attenuates lung fibrosis by way of Mas receptor in acute lung injury

Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome

Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study

A pilot clinical trial of recombinant human angiotensinconverting enzyme 2 in acute respiratory distress syndrome

Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID

Angiotensin-(1-7)-Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells

Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction

The acute prothrombotic effect of aldosterone in rats is partially mediated via angiotensin II receptor type 1

Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis

counterregulates angiotensin II signaling in human endothelial cells

Thrombosis in COVID-19

Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse

ACE2 activation promotes antithrombotic activity

Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP

Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker

Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System

Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19

Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease

Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure

Impact of angiotensinconverting enzyme inhibitors and statins on viral pneumonia

Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during coronavirus disease 2019: beyond confounding

The kinin system--bradykinin: biological effects and clinical implications

The kinin system: biological mechanisms and clinical implications

Differential modulation of murine lung inflammation by bradykinin B1 and B2 selective receptor antagonists

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors

Plasma bradykinin in angio-oedema

Bradykinin-mediated angioedema

A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications

Proliferation of Papers and Preprints During the Coronavirus Disease 2019 Pandemic: Progress or Problems With Peer Review? Adv Chronic Kidney Dis

Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review

Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and COVID-19: Demonstrating the Actionability of Real World Evidence

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Illustrating bias due to conditioning on a collider

Collider bias undermines our understanding of COVID-19 disease risk and severity

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

Timedependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias

Immeasurable time bias in observational studies of drug effects on mortality

Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment

Reducing bias through directed acyclic graphs

Report: Negative Controls to Detect Selection Bias and Measurement Bias in Epidemiologic Studies

Ramipril in High-Risk Patients With COVID-19

Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19. Oral Presentation. ESC Congress

A Randomized Trial of Continuation versus Withdrawal of Renin-Angiotensin System Inhibitors in Patients Hospitalized with Coronavirus Disease

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19

Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol

A structural approach to selection bias

Causal diagrams for encoding and evaluation of information bias

The table 2 fallacy: presenting and interpreting confounder and modifier coefficients

Losartan 25 mg daily Comparator: Placebo (blinded)

Losartan 25 mg daily for 5-14 days Comparator: Placebo (blinded)

Comparator: Placebo (blinded)

FIGURE LEGEND FIGURE 1: Three Proposed Mechanisms of ACEI and ARB Effect in COVID-19

ARB=Angiotensin II Receptor Blocker, ACE2=Angiotensin-Converting Enzyme 2, Ang I=Angiotensin i, Ang II=Angiotensin II, Ang-(1-7)=Angiotensin

Arg 9 ]-bradykinin, B1=G-Protein-Coupled Receptor for DABK, B2=G-Protein-Coupled Receptor for Bradykinin

Red-X's=Downstream Detrimental Effects of ACEI on Normal Pathways, Blue-X's=Downstream Detrimental Effects of SARS-CoV-2 on Normal Pathways This three-panel figure shows proposed mechanisms of ACEIs and ARBs in COVID-19 infection. Mechanism 1: ACEIs and ARBs are Harmful ACEIs and ARBs upregulate ACE2 expression on respiratory epithelial cells, thus increasing available receptors to bind SARS-CoV-2 and facilitate cell entry Mechanism 2: ACEIs and ARBs are Beneficial ACEIs inhibit conversion of Ang I into Ang II, while ARBs inhibit Ang II binding to AT 1 R, thereby both ACEIs and ARBs block Ang II-AT 1 R-mediated deleterious effects in the lungs

The authors would like to acknowledge the resources related to this topic provided by the editors of